Alyeska Investment Group
BXRX

Alyeska Investment Group’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Alyeska Investment Group’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,512
Closed -$389K – 692
2022
Q2 		$389K Hold
11,512
– – ﹤0.01% 536
2022
Q1 		$814K Buy
+11,512
New +$2.13M 0.01% 531
2021
Q1 		– Sell
-58
Closed -$82K – 903
2020
Q4 		$82K Buy
+58
New +$119K ﹤0.01% 496
2020
Q2 		– Sell
-286
Closed -$1.37M – 590
2020
Q1 		$992K Buy
+286
New +$2.7M 0.02% 294

Other funds holding BXRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group's BXRX Position: Q3 2022 in Review

Alyeska Investment Group sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q3 2022, closing a stake of 11,512 shares — an estimated $389K sold.

Alyeska Investment Group first reported a position in BXRX in Q1 2020 and held it in 4 quarters. The position peaked at $992K in Q1 2020. 20 funds tracked by Wall St. Rank hold BXRX as of Q3 2022.

  • Alyeska Investment Group reported no remaining Baudax Bio, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 11,512 Baudax Bio, Inc. Common Stock shares in Q3 2022, an estimated $389K.
  • Alyeska Investment Group first reported a position in Baudax Bio, Inc. Common Stock in Q1 2020 and held it in 4 quarters.
  • Alyeska Investment Group's Baudax Bio, Inc. Common Stock position peaked at $992K in Q1 2020.
  • 20 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q3 2022.

Based on Alyeska Investment Group's 13F filing for Q3 2022, filed 14 Nov 2022.